Dr. Yuki Tanaka MD, PhD

Piyush Goyal Invites Global Pharma Firms to Partner With India

Piyush Goyal invited global pharmaceutical companies to partner with India as the country advances its growth story. He cited India’s ~$60 billion pharma industry, its 1.4 billion-strong market, and the potential for the sector to double in five years.

Blood pressure and ischemic stroke risk in dementia: nationwide cohort findings

A nationwide cohort study in Hypertension Research examines the association between blood pressure and ischemic stroke risk among individuals with dementia. The findings add to evidence that blood pressure matters in cerebrovascular and cognitive-risk management.

PMDA approves ENHERTU for HER2-low breast cancer in Japan

PMDA approved ENHERTU for unresectable or metastatic HER2-low breast cancer in Japan, marking a new regulatory catalyst for Daiichi Sankyo and AstraZeneca. The decision expands the drug’s labeled use in a major market and adds another milestone for investors tracking ENHERTU.

Drug Discovery Technology Market Size Tops USD 80.27 Billion by 2035

BioSpace reports that the drug discovery technology market size is projected to surpass USD 80.27 billion by 2035. This update frames what the figure means for biotech BD teams, investors, and pipeline analysts tracking clinical-trial-linked demand.

Clinical Trials Outsourcing Market Size: 2026-2034 Growth Outlook

Clinical Trials Outsourcing Market Size is projected to rise from USD 54.38 billion in 2026 to USD 92.81 billion by 2034, reflecting a 6.91% CAGR. This plan highlights the scale, regional lead, and top players most relevant for BD teams, investors, and analysts.

Nektar Therapeutics pipeline update: REZPEG clinical programs and regulatory context

Nektar Therapeutics pipeline update: REZPEG clinical programs and regulatory context, with trial facts, status, and a clear split between active development and regulatory context. This plan is built for analysts, BD teams, and investors comparing clinical-stage autoimmune assets.

TGA Australia drug approval pharmaceutical: what the regulator is

TGA Australia drug approval pharmaceutical is a regulator-focused topic, but the evidence here only confirms what the TGA is and where it sits in government. This plan keeps the article tightly grounded in sourced facts and avoids unsupported approval claims.

Areas with Risk of Dengue: CDC map, criteria, and global reach

CDC says nearly half the world’s population lives in areas with dengue risk, spanning the Americas, Africa, the Middle East, Asia, and the Pacific Islands. This update explains the CDC risk classifications and the altitude factor that helps define exposure areas.

Fosun Pharma and AriBio Forge Alzheimer's Option Agreement: Deal Intelligence

Fosun Pharma has entered into a strategic option agreement with AriBio, securing rights to the Alzheimer's drug candidate AR1001. This deal, involving a $60 million option fee, offers significant insights into current Alzheimer's drug development partnerships and their financial structures.

PMDA Regulatory Updates: New Orphan Drug Portal and ASEAN Symposium Open

The Pharmaceuticals and Medical Devices Agency (PMDA) has launched a new website for Orphan Drug Designation and opened registration for the ASEAN-Japan Medical Devices Regulatory Symposium. These updates signal Japan's continued push to reduce drug lag and streamline regulatory pathways.

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Data at ADA 2026

Hengrui Pharma and Kailera Therapeutics presented clinical data for oral ribupatide (HRS9531) at the ADA 2026 conference. The Phase 2 trial showed positive weight loss results, and the partners plan to advance the asset into two new trials.

Eastern Asia Needle-Free Jet Injection Nozzles Market: Trends, Forecast & Insights

This article provides a comprehensive analysis of the Eastern Asia needle-free jet injection nozzles market, including market size, forecast, key trends, and strategic insights for pharmaceutical companies and investors.

NMPA China FDA Drug Approval: 2026 Pathways, Timelines & Impact

NMPA's 2026 regulatory overhaul shortens drug approval-to-market gaps and codifies four green channels for registration. This article breaks down the changes, their impact on cross-border pharma strategy, and what to watch next.

ASCO26: Revolution's Daraxonrasib Phase III Data Reshapes Pancreatic Cancer Odds

At ASCO26, Revolution Medicines presented Phase III data for daraxonrasib, demonstrating a dramatic overall survival benefit in previously treated pancreatic ductal adenocarcinoma. This analysis covers the trial results, regulatory milestones, and strategic implications for pharma teams and investors.

Poly Medicure appoints Indranil Mukherjee as CEO, APAC & India: Strategic implications for pharma BD teams

Poly Medicure has appointed Indranil Mukherjee as Chief Executive Officer for Asia Pacific and India, effective June 1, 2026. This move signals a leadership refresh aimed at accelerating regional growth and market penetration.

Cell Therapy Packaging Market Size & Share Report, 2033: Key Trends and Forecasts

The global cell therapy packaging market is set to expand from $404 million in 2025 to $1.27 billion by 2035, driven by robust cell therapy pipeline growth and regulatory requirements. This report provides a competitive benchmarking analysis for pharma professionals.

Orion Pharma's ODM-212 Shows Favorable Safety in Phase 1/2 TEADES Trial for Advanced Solid Tumours

Orion Pharma announced first results from the Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 in advanced solid tumours. The drug was well tolerated with no dose-limiting toxicities and a 15.6% overall response rate.

Vietnam and India Reshape Middle Power Diplomacy: Market Analysis for Pharma

Vietnam and India are emerging as pivotal middle powers, with Vietnam's 2019 ranking showing the most significant improvement among middle powers alongside New Zealand. This shift creates new opportunities and risks for pharmaceutical market access, supply chain diversification, and strategic partnerships in the Indo-Pacific region.

The Pharma Choke Point: A Strategic Risk for U.S. Pharmaceutical Supply Chains

The Council on Foreign Relations' 'The Pharma Choke Point' report details how U.S. dependence on Chinese pharmaceutical inputs is structural and growing, posing a risk of deliberate supply disruption. This article explains the key findings, implications for pharma teams, and what to watch next.

Ecosystem Over Geography: Life Sciences Location Strategy in APAC

Life sciences companies in Asia-Pacific are shifting from traditional geographic clustering to ecosystem-based location strategies. This article analyzes the key factors driving this change and its implications for strategic planning.

NMPA Drug Approvals Surge in 2025: Record 61 First Global Approvals Signal Accelerated Market Access

The National Medical Products Administration (NMPA) approved a record 61 drugs for first global approval in 2025, spanning modalities from small molecules to cell and gene therapies. New regulatory measures on contract manufacturing and pre-approval importation signal a more agile yet controlled approval environment for BD teams and investors.

Helus Pharma to Participate in the Jefferies Global Healthcare Conference: Strategic Implications for Analysts and BD Teams

Helus Pharma announced its participation in the Jefferies Global Healthcare Conference in New York, where interim CEO Eric So will deliver a fireside chat. This appearance signals the company's intent to engage with institutional investors and highlight its pipeline progress amid a competitive landscape.

Building a Smarter Medical Devices Ecosystem in India: Regulatory Updates

India's recent regulatory updates aim to streamline approvals, boost domestic manufacturing, and attract foreign investment in medical devices. This article outlines the changes, their implications for pharma business development, and answers key questions for investors and analysts.

Cell and Gene Therapy Approvals in China: Latest Regulatory Updates

China's NMPA has approved multiple cell and gene therapies in 2024, signaling a shift toward faster regulatory pathways. This article covers key approvals, implications for pharma teams, and an FAQ section.